Our analysis, incorporating nine studies and 2.3 million patients, demonstrates a methodologically robust, albeit more conservative, 42% reduction in HCC risk, with meta‐regression identifying the choice of comparator—particularly insulin—as the primary source of heterogeneity. The gene discussed is INS; the disease is hepatocellular carcinoma.